Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system

Abstract

Summary A total of 83 specimens of surgically resected tumours from 78 patients with oesophageal cancer were assayed for drug sensitivity using an adhesive tumour cell culture system (LifeTrac CSA assay). Seventyone of 83 specimens had a sufficient number of cells to permit growth in culture and 57 of 71 (80%) were evaluable for drug response. Cells (3 x 103 ml-1 well-l) were cultured for 14 days and exposed to drugs on days 3-8. respectively. The population distribution of IC90 against each drug showed a specific pattern that was very similar among histopathological gradings and stages of the disease. This system appeared to be a clinically applicable drug sensitivity test for human oesophageal cancer.

A feasibility study of chemosensitivity assay by adhesive tumor cell culture system using biopsy specimens for gastric cancer

“…This rate was as high as the rate achieved by ATCCS using resected specimens of esophageal cancer [6], and biopsy specimens of other cancers [5]. One reason for this high evaluation rate was the low incidence of fungal contamination, possible during endoscopic procedure, and the other was the high colony-forming ability of the ATCCS, especially in the undifferentiated adenocarcinoma.…”

“…ATCCS is advantageous in nontumor cell contamination. Baker et al suggest that any potential contamination of the cultures with fibroblast growth in ATCCS is small by morphological study [5] and cytokeratin staining [16], and Terashima et al [6] also report that cancer cell populations were predominant in all samples tested and fibroblast populations were negligible by immunohistochemical analysis in the ATCCS for esophageal cancer. On the contrary, Price et al [22] report that successful growth was obtained in nine (41%) of 22 samples, and fibroblasts, rather than tumor cells, grew in the majority.…”

“…Drug concentrations in the culture medium were as follows: 0.0025, 0.005, 0.01, and 0.015 g/ml of adriamycin (ADM); 0.125, 0.25, 0.5, and 0.75 g/ml of cisplatin (CDDP); 0.015, 0.03, 0.06, and 0.09 g/ml of mitomycin C (MMC); and 0.08, 0.16, 0.32, and 0.48 g/ml 5-fluorouracil (5-FU). These drug concentrations are same as the method of the ATCCS reported by Terashima et al [6] in which the concentrations were determined by 50% and 90% inhibition concentration (IC 90 ) for granulocyte-macrophage colonyforming cells. After 5 days of incubation with the drugs, the medium was changed to culture medium without anticancer drugs, and the cells were cultured again for 7 days.…”

“…The characteristics of this assay may be advantageous over other assays, because only a small amount of biopsy specimen is sufficient to perform the sensitivity assay and a good correlation exists between the assay results and clinical effects. Terashima et al [6] reported that ATCCS evaluation was obtainable in 80% of the cases with esophageal cancer. Here the authors describe ATCCS for gastric cancer focusing on the possibility of utilizing biopsy specimens obtained by a gastroscope, and the relationship between ATCCS results by use of biopsy specimens and the histopathological effects of preoperative anticancer drug administration.…”